The noradrenaline reuptake inhibitor atomoxetine phase-shifts the circadian clock in mice by O'Keefe, S.M. et al.
CG
b
t
o
s
p
m
t
d
i
t
p
m
r
K
e
E
A
c
c
Neuroscience 201 (2012) 219–230THE NORADRENALINE REUPTAKE INHIBITOR ATOMOXETINE PHASE-
SHIFTS THE CIRCADIAN CLOCK IN MICES. M. O’KEEFFE,a J. THOMEb AND A. N. COOGANa*
aDepartment of Psychology, National University of Ireland Maynooth,
o. Kildare, Republic of Ireland
bDepartment of Psychiatry, School of Medicine, University of Rostock,
ermany
Abstract—Circadian rhythms are recurring cycles in physiol-
ogy and behaviour that repeat with periods of near 24 h and
are driven by an endogenous circadian timekeeping system
with a master circadian pacemaker located in the suprachi-
asmatic nucleus (SCN). Atomoxetine is a specific noradren-
aline reuptake inhibitor that is used in the clinical manage-
ment of attention-deficit/hyperactivity disorder (ADHD). In the
current study we examined the effects of atomoxetine on
circadian rhythms in mice. Atomoxetine (i.p.; 3 mg/kg) treat-
ment of mice free-running in constant light (LL) at circadian
time (CT) 6 induced large phase delays that were significantly
different to saline controls. Treatment of animals with atom-
oxetine at CT13 or CT18 did not elicit any significant phase
shifts. We also examined the effects of atomoxetine treat-
ment of animals free-running in constant darkness (DD). Ato-
moxetine treatment at CT6 in these animals leads to more
modest, but significant, phase advances, whereas treatment
at CT18 did not elicit significant phase shifts. The effects of
atomoxetine in LL were attenuated by pretreatment with the
-1 adrenoreceptor antagonist prazosin and were mimicked
y another noradrenaline reuptake inhibitor, reboxetine. Fur-
her, atomoxetine treatment at CT6 induced a downregulation
f c-Fos and CLOCK in the SCN, but did not alter the expres-
ion of PER2 and BMAL1. Atomoxetine during the night
hase did not alter any of these factors. Atomoxetine treat-
ent preceding a light pulse at CT15 enhanced the magni-
ude of the photic-phase shift, whereas it altered photic in-
uction of the immediate early gene products c-Fos and ARC
n the SCN. These data indicate that atomoxetine can reset
he circadian clock and indicate that part of the therapeutic
rofile of atomoxetine may be through circadian rhythm
odulation. © 2011 IBRO. Published by Elsevier Ltd. All
ights reserved.
ey words: atomoxetine, circadian, suprachiasmatic, rebox-
tine, c-Fos, clock.
Circadian rhythms are near 24-h recurring cycles in a host
of behavioural and physiological parameters that are un-
derpinned by an endogenous circadian timekeeping sys-
tem (Reppert and Weaver, 2002). In mammals the master
pacemaker of this circadian system is located in the su-
prachiasmatic nucleus (SCN) of the anterior hypothala-
*Corresponding author. Tel: 353(8)-1-7086624; fax: 353(8)-1-7084767.
-mail address: andrew.coogan@nuim.ie (A. N. Coogan).
bbreviations: ADHD, attention-deficit/hyperactivity disorder; CT, cir-
adian time; DD, constant darkness; IEG, immediate early gene; LL,
onstant light; NA, noradrenaline; SCN, suprachiasmatic nucleus.
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219mus, which receives afferent input allowing the entrain-
ment of the circadian clock to appropriate sensory and
environmental time cues (zeitgebers), the dominant one
being light (Dibner et al., 2010). The molecular machinery
that allows for stable generation of such circadian rhythms
is now known to consist of a panel of clock genes that
regulate both their own expression and also those of clock-
controlled genes, with various studies demonstrating that
approximately 10% of the transcriptome of various tissues
displays significant circadian rhythmicity (Hogenesch et
al., 2003).
The SCN is known to receive input from a number of
midbrain and brainstem regions (Moga and Moore, 1997)
as well as projecting indirectly to key brainstem areas such
as the locus coereleus in order to drive circadian rhythms
in arousal (Aston-Jones et al., 2001). Some input path-
ways have received sustained attention in the research
literature (e.g. the serotoninergic input; Morin and Allen,
2006), whereas other systems have received somewhat
less attention. The SCN is known to receive noradrenergic
innervation (Cagampang et al., 1994; Jacomy and Bosler,
1995), with noradrenaline (NA) levels displaying rhythms in
the rat and hamster SCN (Semba et al., 1984; Cagampang
et al., 1994) as well as throughout the rest of the brain (e.g.
Manshardt and Wurtman, 1968). The role of NA in regu-
lating SCN function is not clear, although it has been
proposed that NA regulates the expression of the key SCN
neuropeptides arginine vasopressin and vasoactive intes-
tinal polypeptide (Vacher et al., 2003, 2004). Further, it has
been noted that the SCN expresses both -1 and -2
adrenoreceptors (Morien et al., 1999). There have been a
limited number of studies examining the effects of adren-
ergic agents on circadian organization of behaviour and
clock gene regulation (Rosenwasser, 1996; Terazono et
al., 2003; Wongchitrat et al., 2009) with many issues re-
garding the adrenergic regulation of the master SCN cir-
cadian clock remaining unascertained. One such issue is
the extent to which medication used to treat affective and
other psychiatric disorders, which target the noradrenergic
system, may exert their effects through a circadian modu-
lation. For example, the noradrenaline reuptake inhibitor
reboxetine is licensed for use in the treatment of major
depression, which itself has long been associated with
circadian desynchrony (Wirz-Justice, 2009). Further, an-
other noradrenaline reuptake inhibitor, atomoxetine, is li-
censed for the treatment of attention deficit/hyperactivity
disorder (ADHD), which again has been associated with
phase misalignment of the circadian clock (Van Veen et
al., 2010). Given that correction of these circadian discrep-
ancies is associated with symptom relief (Coogan and
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S. M. O’Keeffe et al. / Neuroscience 201 (2012) 219–230220Thome, 2011), it is of interest to inquire as to the actions of
noradrenergic modulating drugs on circadian rhythms. To
this end we have studied the effects of atomoxetine on
circadian rhythms in the mouse in order to gain insight into
putative mechanisms that may be of importance in human
psychopharmacology. As non-photic stimuli that phase-
shift the clock also suppress expression of clock genes in
the SCN (e.g. Maywood et al., 1999) we have also exam-
ined the effect of atomoxetine on the expression of a
number of clock gene protein products.
EXPERIMENTAL PROCEDURES
Animals and housing
Male C57BL/6 mice (22–25 g) obtained from Harlan Laboratories
(Leicestershire, UK) were used throughout this study. Animals
were singly housed in polypropylene cages equipped with running
wheels (11 cm diameter) with food and water available ad libitum
nd temperature held constant at 211 °C and humidity at
010%. Cages were then housed in an environmental isolation
abinet to allow for full control of the photic environment. They
ere illuminated using a fluorescent white light source, with aver-
ge illuminance of 250 lx at the level of the cage floor when lights
ere on. Bedding was changed every 14 days, and never in the
eriod leading up to or after a pharmacological intervention. All
xperiments were approved by the Research Ethics Committee,
ational University of Ireland Maynooth and licensed by the Irish
epartment of Health and Children and conformed to the Euro-
ean Communities Council Directive of 24 November 1986 (86/
09/EEC). All efforts were made to reduce the number of animals
sed in the study, as well as any pain and suffering.
Circadian rhythm monitoring
Wheel running was monitored through microswitches attached to
the running wheels communicating with the Chronobiology Kit
(Stanford Software Systems, CA, USA) to allow for production of
actograms of wheel-running behaviour. Before any pharmacolog-
ical intervention animals were allowed to free-run for 2 weeks to
allow for analysis of stable baselines of circadian factors. Phase
shifts were rated by two to three independent observers blind to
the treatments by means of the line-of-best-fit method through
activity onsets for 7 days before and after any intervention. Phase
shifts were calculated as the difference in the regression lines
before and after the intervention, calculated on the day following
the intervention. Period length and rhythm strength were obtained
from Poisson Periodograms in the Chronobiology kit.
Drugs
Atomoxetine HCl was obtained from Tocris Bioscience (Bristol,
UK), dissolved in 0.9% sterile saline and administered i.p. at a
dose of 3 mg/kg, a dose which has been previously shown to elicit
neurochemical effects in rodent brain (e.g. Bymaster et al., 2002).
Prazosin and reboxetine were also obtained from Tocris Biosci-
ence and administered at doses of 4 mg/kg i.p. and 20 mg/kg i.p.,
doses previously determined to be effective in similar approaches
(Cryan et al., 2004).
Effects of atomoxetine and reboxetine on free
running circadian rhythms
In these experiments, animals were maintained in cages with
running wheels under a 12:12 light:dark cycle for 2 weeks before
being released into constant conditions (either constant light (LL)
or constant darkness (DD)). Both photic backgrounds were used,as previous research has indicated that LL enhances phase-
shifting in response to some stimuli (Knoch et al., 2004). Animals
were allowed to free run for 2 weeks before the first drug treat-
ment. Animals (n8 for LL and n8 for DD) received an injection
of atomoxetine (3 mg/kg) and an injection of saline at circadian
time (CT) 6, each treatment separated by 14 days before being
crossed over to the other treatment, such that each animal re-
ceived both atomoxetine and vehicle. Further to this, each animal
then received atomoxetine or saline at CT18.
To further test the phase-specificity of atomoxetine’s actions a
separate group of mice (n8) were free-run in LL and in a counter-
balanced cross-over design received atomoxetine/saline at CT13
followed by the complementary treatment 2 weeks later, followed
by a further 14-day free running to allow for accurate rating of the
stable phase shift. Timepoints were selected on the basis of
previous studies of phase-dependence of non-photic and pharma-
cological manipulations that produce phase shifts, which typically
indicated efficacy when applied in the subjective day but not the
subjective night.
To test whether another noradrenaline reuptake inhibitor, re-
boxetine, would have a similar effect as to atomoxetine, mice
(n8) were free-run in LL for 2 weeks before receiving either
reboxetine (20 mg/kg, i.p.) or saline, before receiving the comple-
mentary treatment 14 days later, followed by a further 14 days of
free running. To test whether the effects of atomoxetine were
modulated by an adrenergic receptor antagonist, prazosin, a
group of mice (n8) were free-run in LL for 14 days before
receiving treatment with atomoxetine at CT6 coupled with either
prazosin treatment (4 mg/kg, i.p.; n4) or saline treatment (n4)
30 min before the atomoxetine treatment (so at CT5.5). After a
further 14 days animals again received atomoxetine at CT6 pre-
ceded by either saline or prazosin in a cross-over design, so that
each animal received atomoxetine plus prazosin and atomoxetine
plus saline.
Effects of atomoxetine in modulating photic phase
shifts
In this experiment we examined whether atomoxetine pretreat-
ment would alter light-induced phase shifts of the circadian
rhythm. Mice (n12) were free-run in DD for 2 weeks, before
receiving a 30 min light pulse (150 lx) at CT15-CT15.5, the circa-
dian phase at which a maximal phase delay is elicited in mice (e.g.
Pendergast et al., 2010). Thirty min before the light pulse animals
received an i.p. injection of either atomoxetine (3 mg/kg) or saline.
Animals were then allowed to free run for another 14 days before
receiving another light pulse at CT15 crossed over to the comple-
mentary atomoxetine/saline treatment, so that each animal re-
ceived two light pulses at CT15, one preceded with atomoxetine
and one with saline.
Effects of atomoxetine on clock gene production
expression in the SCN
At the end of each behavioural experiment animals received a
final treatment and then were killed by cervical dislocation and
their brains removed and fixed for immunohistochemical process-
ing. Animals received atomoxetine or saline at CT6 in LL, atom-
oxetine or saline at CT13 in LL, atomoxetine or saline at CT6 in
DD, reboxetine or saline in LL at CT6 and atomoxetine at CT6
preceded by saline at CT5.5 or atomoxetine at CT6 preceded by
prazosin at CT5.5 (n4 for each treatment group). Animals were
sampled and brains removed 2 h following the final treatment. For
light pulse experiments animals received saline plus a 30-min light
pulse at CT15 (n4) or atomoxetine at CT14.5 followed by a
30-min light pulse at CT15 (n4) before being sampled 1 h after
the onset of the light pulse. Brains were immersion fixed as
previously described (Beynon et al., 2009) before being cryopro-
tected in 30% sucrose. Brains were then sectioned coronally into
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S. M. O’Keeffe et al. / Neuroscience 201 (2012) 219–230 22130 m sections on a freezing stage sledge microtome (Leica, UK).
ections containing the SCN were then processed for immuno-
istochemistry using a standard avidin-biotin complex (ABC)/nick-
l-DAB protocol (e.g. Beynon et al., 2009). Briefly, following
eroxidase inactivation and blocking with serum, sections were
ncubated with primary antibody in 1% normal goat/rabbit serum
as appropriate for the primary antibodies used) overnight before
eing developed with biotinylated secondary antibodies (1:400)
nd ABC (0.4%; Vector Laboratories, Peterborough, Cam-
ridgeshire, UK). Reaction product was visualized using nickel-
AB. All sections were reacted under the same conditions for the
ame amount of time across treatment groups for each antibody to
nsure equivalence of staining and minimization of inter-run vari-
bility. Primary antibodies used in this study were c-Fos (rabbit
olyclonal, sc-52, diluted 1:2000), CLOCK (goat polyclonal,
c6928, diluted 1:500), BMAL-1 (rabbit polyclonal, sc-48790, di-
uted 1:500) and PER2 (rabbit polyclonal, sc-25363, diluted
:500); all from Santa Cruz Biotechnology (Heidleberg, Germany).
he use and specificity of these antibodies have been previously
escribed (e.g. Wyse and Coogan, 2010; Borgs et al., 2009), but
o confirm this, where available, the immunizing peptides were
sed in adsorption controls and ablated immunostaining. For pho-
ic stimulation experiments similar protocols were used with the
ame c-Fos antibody as above and a rabbit polyclonal antibody
aised against the immediate early gene product ARC (Santa Cruz
c-15325). Both c-Fos and ARC are immediate early genes whose
xpression in the SCN is upregulated by photic stimulation (Korn-
auser et al., 1990; Nishimura et al., 2003).
After being dehydrated, delipified and cover-slipped, sections
ere analysed on an Olympus BX51 microscope equipped with a
P-12 digital camera. Sections across the rostro-caudal extent of
he SCN were examined. There were at least six SCN sections per
nimal examined. Cell counting was by an observer blinded to the
reatment. Only densely, unambiguously stained cells were
ounted as being immunopositive. For graphical representation of
ell counts across different antigens, cell counts for each saline-
nd drug-treated animal were normalized to the overall average
ounts for the appropriate control group (e.g. for c-Fos counts in
he SCN after saline or atomoxetine treatment in LL at CT6 counts
or each animal were normalized to the average c-Fos count for
he saline group in LL treated at CT6).
Statistical analysis
Data were analysed using a mix of within-groups and between-
groups t-tests and factorial ANOVAs, with Bonferroni corrections
made for multiple comparisons where required. Test type used is
quoted throughout the results section. All data are presented as
meanstandard error of the mean. All statistical analysis was
carried out with PASW statistics 18 (IBM) with significance set at
P0.05.
RESULTS
Atomoxetine phase shifts circadian locomotor
rhythms
We examined the effects of atomoxetine administration at
different times of the circadian cycle (CT6, CT13, CT18)
and against different photic backgrounds (LL vs. DD) on
free-running circadian locomotor rhythms. Two-way facto-
rial ANOVA with time of treatment and photic background
as the independent variables reveals main effects of time
of treatment (F(2,32)60.1, P0.001) and photic back-
ground (F(1,32)63, P0.001), as well as a significant
interaction between time of treatment and photic back-
ground (F(1,32)60, P0.001) on the phase shifts elicitedby atomoxetine. Further examination of these effects re-
vealed that atomoxetine treatment at CT6 in LL elicited a
large phase delay of the behavioural circadian rhythm
(3.150.27 h for atomoxetine vs. 0.610.18 h for sa-
line; P0.001 paired t-test; Fig. 1A, B). When the effects of
atomoxetine on rhythms in DD were examined it was found
that treatment at CT6 elicited a moderate but significant
phase advance of the rhythm (0.960.22 h for atomox-
etine vs. 0.090.18 for saline, P0.001 by paired t-test;
Fig. 1C, D). There were no significant phase shifts induced
when atomoxetine was administered in LL at CT13
(0.640.21 h for atomoxetine vs. 0.210.17 h for saline;
Fig. 3) or at CT18 (0.410.11 h for atomoxetine vs.
0.570.19 h for saline; Fig. 1E). Treatment with atomox-
etine at CT18 in DD also did not elicit a significant phase
shift (0.230.1 h for atomoxetine vs. 0.120.13 h for
saline; Fig. 1E).
There were no significant changes in the period or the
strength of the free-running rhythm following atomoxetine
treatment in either LL or DD (data not shown), nor was
there any marked acute response directly following atom-
oxetine treatment (e.g. no unexpected periods of locomo-
tor behaviour).
Effects of atomoxetine on clock gene and immediate
early gene expression in the SCN
We examined the effect of atomoxetine treatment on c-
Fos, CLOCK, PER2 and BMAL1 expression in the SCN at
CT6 in both LL and DD. Two-way ANOVA with treatment
and photic background as the fixed factors reveal that
there was a main effect of treatment (F(1,15)22.3,
P0.001) but not of photic background nor was there a
treatmentphotic background interaction (both P0.05).
For CLOCK expression there were main effects for treat-
ment (F(1,15)6.3, P0.05) and photic background
(F(1,15)27.8, P0.001) as well as significant interaction
between treatment and photic background (F(1,15)28.1,
P0.001). There were no main effects of treatment or
photic background on BMAL1 or PER2 expression, nor
were there significant interactions between treatment and
photic background for both of these antigens (all P0.05).
Further pairwise analysis revealed that treatment
with atomoxetine at CT6 in LL elicited a decrease in the
expression of c-Fos and CLOCK expression in the SCN
(P0.01 compared with saline controls by independent
t-test), but not of BMAL1 or PER2 expression (Fig. 2).
Atomoxetine treatment in DD at CT6 induced a signifi-
cant decrease in c-Fos expression in the SCN (P0.05
compared with saline controls by independent t-test),
but not of CLOCK, BMAL1 or PER2 (Fig. 3A). Treatment
with atomoxetine in LL at CT13 did not elicit any signif-
icant changes in expression of c-Fos, CLOCK, BMAL-1
or PER2 (Fig. 3B).
Effects of reboxetine on circadian rhythms and clock
gene product expression
In order to examine whether other specific noradrenaline
reuptake inhibitors may exert similar effects as atomox-
etine, animals in LL were treated with reboxetine or saline
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S. M. O’Keeffe et al. / Neuroscience 201 (2012) 219–230222(20 mg/kg, i.p.) at CT6. This was found to result in a
significant phase delay following reboxetine treatment
when compared with saline (2.080.27 h vs. 0.24
0.18 h for saline control; P0.01 by paired t-test; Fig. 4A,
). Reboxetine did not elicit any significant alterations in
he free-running period nor in the amplitude of the circa-
ian rhythm. When the SCN of animals treated with rebox-
tine at CT6 in LL were examined it was shown that,
imilar to atomoxetine, treatment resulted in a suppression
f c-Fos and CLOCK (P0.05 and P0.01compared with
aline and controls respectively by independent t-test), but
Fig. 1. Atomoxetine induces phase shifts of locomotor circadian rhyth
with atomoxetine (ATO) and saline (treatments indicated by the arrows
indicate lines of best fit through the activity onsets, where activity onse
at CT6 in LL (*** denotes P0.001; n8). (C) Atomoxetine induces m
tomoxetine (ATO) treatment at CT in DD produces a phase advance
aline at CT6 in DD (** denotes P0.01; n8). (E) Atomoxetine treat
hifts produced by atomoxetine or saline in LL at CT13 or CT18 and
aline treatments. For interpretation of the references to colour in thisot of BMAL1 and PER2 (Fig. 4C).Effects of pretreatment with prazosin on
atomoxetine-induced effects
Animals were treated with atomoxetine in LL at CT6
after being treated with either prazosin or saline. Pre-
treatment with prazosin significantly attenuated the ato-
moxetine-induced phase delay (0.450.17 h for pra-
zosin and atomoxetine treatments compared to
2.260.18 h for saline and atomoxetine; P0.001 by
paired t-test; Fig. 5A, B). When the effects of prazosin
pretreatment on atomoxetine-induced effects in the SCN
ample double plotted actogram of a mouse free-running in LL treated
Note the large delay induced by atomoxetine treatment. Diagonal lines
d as CT12. (B) Mean phase shifts produced by atomoxetine or saline
ase advances in DD. Sample double plotted actogram showing that
ximately 60 min. (D) Mean phase shifts produced by atomoxetine or
he night phase does not induce significant phase shifts. Mean phase
in DD. There are no significant differences between atomoxetine and
gend, the reader is referred to the Web version of this article.ms. (A) S
) at CT6.
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significantly less c-Fos and CLOCK than those sections
from animals pretreated with prazosin before atomox-
etine administration (P0.05 for prazosinatomoxtine
vs. salineatomoxetine by paired t-test; Fig. 5C).
Effects of atomoxetine on light-induced phase shifts
Pretreatment with atomoxetine before a light pulse at
CT15 in animals in DD led to a significant enhancement
of the photic phase shift compared with that produced by
saline treatment and photic stimulation (2.20.13 h for
atomoxetine plus light pulse vs. 1.890.15 h for saline
plus light pulse; P0.01 by between groups t-test; Fig.
6A, B). Further, when the effects of atomoxetine on
light-induced c-Fos and ARC were examined in the SCN
to test whether photic responsiveness was altered at the
molecular level, it was found that atomoxetine-treated
animals expressed significantly less SCN c-Fos and
ARC than saline-treated controls following a light pulse
in the early subjective night (P0.01 for both antigens
by independent t-test; Fig. 6C, D).
DISCUSSION
The results of the present study describe for the first time the
Fig. 2. Atomoxetine suppresses c-Fos and CLOCK expression in the S
SCN 2 h following a treatment with either atomoxetine or saline at CT6
and PER2 expression in the SCN compared with saline treatment grou
legend, the reader is referred to the Web version of this article.phase-resetting properties of specific noradrenaline reuptakeinhibitors that are used in clinical practice for the manage-
ment of ADHD and depression. As such it is the first report
suggesting that drugs that specifically target the noradrener-
gic system can phase shift the circadian clock as assessed at
the behavioural level. Somewhat surprisingly we report that
treatment with atomoxetine in the subjective day against a
background of constant light leads to large magnitude
phase delays, whereas the same treatment in constant
darkness leads to a more modest phase advance. Treat-
ments in either LL or in DD in the night phase did not lead
to significant phase alterations. In a similar manner the
effects of atomoxetine on c-Fos and CLOCK expression
were limited to subjective day treatments, in a similar
manner that has been described for other non-photic stim-
uli (Mikkelsen et al., 1998; Maywood et al., 1999). This
phase specificity is typical of non-photic stimuli (Mistl-
berger and Skene, 2004) and has been described previ-
ously for a number of psychoactive substances (Turek and
Losee-Olson, 1986; Meijer et al., 2000). However, the
large phase delays elicited by atomoxetine (and rebox-
etine) treatment in LL during the day are not typical follow-
ing non-photic manipulation in wild-type nocturnal animals,
with the smaller magnitude phase advances seen in DD
being more typical of non-photic phase shifts. For exam-
ple, a non-photic manipulation applied in LL that is rela-
Sample photomicrographs of c-Fos, CLOCK, BMAL1 and PER2 in the
le bar100 m. (B) Effects of atomoxetine on c-Fos, CLOCK, BMAL1
tes P0.01. For interpretation of the references to colour in this figureCN. (A)
in LL. Scatively well studied is the presentation of dark pulses. These
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when applied during the middle of the subjective day (Bou-
los and Rusak, 1982) and so can be contrasted with the
larger phase delays elicited by atomoxetine in LL in the
current study. However given that the mechanisms of
phase-resetting by dark pulses may entail a photic as well
as non-photic component (e.g. Coogan and Piggins,
2005), such comparisons must be made with caution.
There is a report that large magnitude phase delays can be
elicited by treatment with an inhibitor of casein-kinase 1 in
he subjective day (Badura et al., 2007), and so the reset-
ing reported here for atomoxetine in LL is not
nprecedented.
utative mechanisms of atomoxetine actions of
ircadian rhythms
he SCN receives sparse noradrenergic innervations (Van
en Pol et al., 1985; Cagampang et al., 1994), and the
CN displays both diurnal and circadian rhythms in its NA
ontent, with levels peaking in the middle of the subjective
ay or the lights on period (Semba et al., 1984; Cagam-
ang et al., 1994), in contrast to rhythms in the rest of the
rain (Manshardt and Wurtman, 1968). Noradrenergic fi-
Fig. 3. Atomoxetine effects on c-Fos, CLOCK, BMAL1 and PER2 in t
DD at CT6 with atomoxetine results in suppression of c-Fos, but no
treatment in LL at CT13 does not induce any significant changes in an
figure legend, the reader is referred to the Web version of this articleres appear to regulate expression of the neuropeptidesIP and AVP (Vacher et al., 2003, 2004), and these pep-
ides are known to be key mediators of SCN circadian
unction (Welsh et al., 2010). Other studies have shown
hat monoamine biosynthetic and catabolic pathways are
nder significant circadian control (Sleipness et al., 2007;
ampp et al., 2008). Within the SCN, there is evidence that
here are circadian fluctuations in ligand binding to -1, but
not -2 adrenoreceptors (Morien et al., 1999). These find-
ings suggest that the noradrenergic system is under con-
siderable circadian control and matches with our findings
of phase-specificity in the action of atomoxetine. The sim-
plest explanation is that atomoxetine exerts its circadian
effects directly in the SCN by blocking noradrenaline re-
uptake during the day phase, when endogenous noradren-
aline levels are highest, and is ineffective during the night
phase when endogenous levels are lowest, perhaps indi-
cating the reuptake inhibition would have minimal effects at
this phase. However, we must presume that atomoxetine
(or reboxetine) may exert their effects indirectly through
extra-SCN sites, perhaps by modulating other transmitter
systems (e.g. acetylcholine, Tzavara et al., 2006) that may
impact on circadian timing. Further pharmacological dis-
section of the circadian effects of atomoxetine and other
noradrenergic agents will be required to further examine
n the day in DD or during the night in LL. (A) Treatment of animals in
, BMAL1 or PER2 in the SCN. * Denotes P0.05. (B) Atomoxetine
ntigens examined. For interpretation of the references to colour in thishe SCN i
t CLOCKthis issue.
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he effects of manipulating the noradrenergic system
harmacologically on circadian rhythms. Penev et al.
1993, 1994) reported that monoamine depletion inhibits
heel running, phase advanced behavioural rhythms in
D, lengthened free-running period and attenuated pho-
ically and non-photically induced phase advances.
hronic treatment with the -1 agonist clonidine resulted
in a significant shortening of the free-running period of
rats, an effect that was reversed upon washout (Rosen-
wasser, 1989, 1996). Weber et al. (2009) report that
treatment with reboxetine at ZT10 inhibits wheel running
activity in the early night phase, and this finding is in
general agreement with previous studies showing that
noradrenaline reuptake inhibitors decrease locomotor
behaviour (e.g. Mitchell et al., 2006). Given that atom-
oxetine is efficacious in producing phase shifts in the
current study when treatment occurs during the behav-
Fig. 4. Reboxetine treatment during the day period in LL induces s
reatment with reboxetine, but not saline, at CT6 in LL produces a phas
* Denotes P0.01. (C) Treatment with reboxetine at CT6 in LL suppr
PER2 expression. * Denotes P0.05. For interpretation of the referen
his article.iourally quiescent day phase it seems unlikely that its Ieffects are mediated by suppression of spontaneous
wheel-running behaviour.
Clock and immediate early gene regulation by
atomoxetine
Given that in order to effect a change in circadian behav-
iour at the whole animal level, phase-shifting stimuli must
act on the molecular/neuronal mechanisms that underpin
circadian timing, we examined the effects of atomoxetine
and reboxetine on the expression of clock gene products
CLOCK, BMAL1, PER2 and the immediate early gene
(IEG) c-Fos. A number of studies have previously exam-
ined the effects of adrenergic agents on clock gene ex-
pression in a variety of cell and tissue types. Perhaps the
best characterized system is the noradrenergic modulation
of pineal circadian function, where per1 and cry1 expres-
sion is under noradrenergic regulation through -recep-
ors, but not bmal1 or rev-erb-a (Wongchitrat et al., 2009).
phase delays. (A) Sample double-plotted actogram illustrating that
B) Mean phase shifts produced by reboxetine and saline in LL at CT6.
SCN expression of c-Fos and CLOCK, but does not alter BMAL1 or
lour in this figure legend, the reader is referred to the Web version ofignificant
e delay. (
esses the
ces to con cultured spinal astrocytes, per1, but not clock or per2, is
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S. M. O’Keeffe et al. / Neuroscience 201 (2012) 219–230226upregulated by noradrenaline in an -1 and -2 receptor
ependent manner, whereas bmal1 was regulated in a
er1 dependent manner (Sugimoto et al., 2011). In C6
lioma cells regulation of per1 by noradrenaline is  re-
eptor dependent (Morioka et al., 2010). Akiyama et al.
2003) report that noradrenaline upregulates per1 and
per2 in fibroblasts and liver in an -1 receptor dependent
anner. Clonidine (an -1 agonist) treatment was reported
ot to alter PER2 expression in the SCN, but did so at the
tart of the light phase in the central amygdala and the bed
ucleus of the stria terminalis (Hood et al., 2011). The
nvolvement of -1 receptors in these findings is congruent
with our present findings that the effects of atomoxetine
were significantly attenuated by the -1 specific antagonist
razosin.
With regards to the changes in c-Fos and CLOCK
xpression in the SCN elicited by atomoxetine and rebox-
tine, numerous previous studies have indicated that a
ide variety of non-photic stimuli that elicit behavioural
Fig. 5. Pretreatment with prazosin attenuates the atomoxetine induced
prazosin blocks the atomoxetine-induced phase delay when mice are t
when it is preceded by either saline or prazosin. ** Denotes P0.01.
-Fos and CLOCK in the SCN. * Denotes P0.05. For interpretation o
ersion of this article.hase shifts also suppress SCN levels of c-Fos (e.g. Mik-elsen et al., 1998; Maywood et al., 1999; Antle and Mis-
lberger, 2000; Coogan and Piggins, 2005), so the sup-
ression of c-Fos observed in this study fits in with the
eneral picture associated with non-photic phase shifting.
s far as we know there are no published examples of
LOCK expression following non-photic stimulation in the
CN, although in other paradigms calorie restriction, inter-
eron- and age are all found to downregulate CLOCK
expression (Wyse and Coogan, 2010; Mendoza et al.,
2007; Koyanagi and Ohdo, 2002). It is plausible that the
suppression of CLOCK we see is because of post-trans-
lational processed regulating protein stability, rather than
transcriptionally mediated effects (Mehra et al., 2009). Ac-
cording to the accepted model of the clock gene cycle
(Dibner et al., 2010), alteration in the availability CLOCK to
form CLOCK/BMAL-1 heterodimers and drive transcription
of per/cry genes could lead to an alteration of the phase of
the molecular clock that could be translated into a phase
shift at the whole animal level. It should be noted here that
(A) Sample double-plotted actogram illustrating that pretreatment with
CT6 in LL. (B) Mean phase shifts produced by atomoxetine treatment
sin pretreatment attenuates the atomoxetine-induced suppression of
ences to colour in this figure legend, the reader is referred to the Webeffects.
reated at
(C) Prazoin the current study we have used immunohistochemistry
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sessing mRNA. Given the relatively long lag time between
clock gene mRNA expression and clock gene protein prod-
uct synthesis (e.g. Field et al., 2000) it is possible that the
2 h after treatment timepoint we sampled at does not allow
sufficient time for PER2, BMAL1 or CLOCK upregulation.
Given that non-photic stimuli elicit marked downregulation
of per2 mRNA (dark pulses, Mendoza et al., 2007; forced
activity, Maywood et al., 1999), it is interesting to compare
the current results showing no modulation of PER2 by
atomoxetine. In future studies it will be of interest to exam-
ine the effect of atomoxetine on PER1 expression in the
SCN as well as regulation of other clock components such
as CRY1/2 and REV-REB-.
ifferential effects of atomoxetine in LL vs. DD
e choose to examine the effects of atomoxetine in LL as
ell as DD because of the fact that a number of previous
tudies have indicated that circadian responses to phar-
acological manipulations of monoaminergic systems is
otentiated by exposure to LL. For example, prior LL ex-
osure markedly increased the phase-resetting actions of
he serotoninergic agonist 8-OH-DPAT in the hamster (2
Fig. 6. Effects of atomoxetine on photically induced phase delays and
freer-running in DD who receives a 30 min light pulse at CT15 in c
phase-delays achieved by a light pulse at CT15 coupled with eit
photomicrographs illustrating SCN expression of c-Fos and ARC in th
or atomoxetine. Scale bar100 m. (D) Mean expression levels of c-F
r atomoxetine. ** Denotes P0.01. For interpretation of the referenc
his article.ays LL exposure plus 8-OH-DPAT resulting in phase Hhifts as large as 12 h), although this potentiating effect of
L attenuated after 3 weeks exposure to LL (Knoch et al.,
004). This LL-induced enhancement of non-photic phase
hifting was also seen for phase resetting induced by sleep
eprivation and neuropeptide-Y treatment as well as for
e-entrainment to shifted light:dark schedules, and is as-
ribed to LL abolishing the rhythmic release of serotonin in
he SCN, although 8-OH-DPAT-induced clock gene ex-
ression is not altered (Knoch et al., 2004; Duncan et al.,
005; Kaur et al., 2009). Altered serotoninergic tone in the
CN in LL is one possible explanation for the differences in
irection and magnitude of phase shift produced by atom-
xetine in LL and DD. There are also other possible ex-
lanations for these differences.
LL is known to induce weakening of the SCN circadian
scillations and behavioural rhythms, increased circadian
eriod, suppressed activity and can induce behavioural
rrhythmicity or splitting (Chen et al., 2008). The limit cycle
heoretical model of the SCN pacemaker indicates that
anipulations that induce circadian modifications of mod-
st magnitude (as produced here by atomoxetine in DD)
ay result in much larger phase shifts if the circadian
mplitude is weakened sufficiently (Jewett et al., 1991).
induced c-Fos and ARC in the SCN. (A) Sample actogram of a mouse
n with either saline or atomoxetine treatment at CT14.5. (B) Mean
e or atomoxetine pretreatments. ** Denotes P0.01. (C) Sample
h after a light pulse at CT15 in animals pretreated with either saline
RC in the SCN following a CT15 light pulse preceded by either saline
our in this figure legend, the reader is referred to the Web version ofphotically
onjunctio
her salin
e SCN 1
os and Aowever a recent study by vanderLeest et al. (2009) has
i
t
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amplitude circadian rhythms in behaviour, photic stimula-
tion actually induces larger amplitude phase shifts, com-
pared with animals in long days with lower amplitude
rhythms. Therefore it may be the case that LL-induced
weakening of the circadian amplitude may not be related to
the magnitude and direction of the atomoxetine-induced
phase shifts reported here. Genetic alterations that result
in alteration of the period of the circadian cycle also influ-
ence the magnitude of non-photic phase shifts (Mrosovsky
et al., 1992) or the direction of these shifts (Challet et al.,
2000). Therefore it is possible that the lengthening effect of
LL on the behavioural rhythm contributes to the differences
observed in the atomoxetine-induced effects in LL com-
pared with DD. Interestingly Rosenwasser (1989, 1996)
noted that the effects of the noradrenergic agonist cloni-
dine on shortening free-running circadian period in rats
was dependent on photic background through effects on
the baseline circadian period.
Another, perhaps interconnected possibility is that LL
induces changes in SCN clock gene product expression,
resulting in either ablated rhythmicity in PER2 (Muñoz et
al., 2005; Chen et al., 2008) or significant phase delays of
PER2 (Sudo et al., 2003). LL also alters the SCN expres-
sion of c-Fos, PER1 and activated ERK (Sumová and
Illnervoá, 2005; Coogan and Piggins, 2005). Thus the
effects of photic background on atomoxetine-induced ef-
fects may be mediated through LL-induced alterations in
clock gene expression. Of interest here is the finding that
heterozygous Clock/ mice, exposure to novel wheels
induces a phase delay, although the same manipulation in
wild-type mice results in a phase advance (Challet et al.,
2000). Given the effects of atomoxetine treatment in LL
(delays) vs. DD (advances), and the suppression of
CLOCK by treatments in LL but not DD, there may be a
differential role played by CLOCK in determining the type
of phase shift that is obtained.
Modulation of photic phase shifting and c-Fos and
ARC induction by atomoxetine
Aside from the effects that atomoxetine exerts on phase-
shifting free running rhythms described in this study, we
also demonstrate that atomoxetine can alter the effects of
light on circadian rhythms and SCN IEG expression by
light. We show that atomoxetine pretreatment enhances
the magnitude of the phase delay elicited by a light pulse in
the early subjective night while also downregulating the
photic-induction of c-Fos and ARC. The only other study to
examine noradrenergic modulation of photic phase-shifting
is by Gannon and Millan (2007) who examined the effects
of reboxetine on light-induced phase advances in ham-
sters and found no significant effect. There are a couple of
possible reasons for the apparent discrepancy between
atomoxetine’s enhancement of photically induced phase
delays in the current study and the effects of reboxetine in
hamsters. These include differences in pharmokinetics be-
tween atomoxetine and reboxetine (Bymaster et al., 2002),
species differences between mouse and hamster and dif-ferent effects in the delay versus the advance portions of
the photic phase-response curves.
Both c-Fos and ARC are known to be upregulated in
the SCN in response to photic stimulation in a phase-
dependent manner (Kornhauser et al., 1990; Nishimura et
al., 2003). These antigens represent two classes of IEGs,
c-Fos being a regulatory transcription factor and ARC be-
ing a biological effector protein associated with synaptic
plasticity (Link et al., 1995), and thus their involvement in
the cellular processes underpinning photic resetting may
differ. The regulation of both c-Fos and ARC photic induc-
tion by atomoxetine would indicate a common component
on their photic induction pathway in SCN cells that is
amenable to noradrenergic modulation. Various pharma-
cological manipulations have been found to enhance pho-
tic phase-shifting effects, as we describe here, and these
enhancements in the behavioural response are not always
mirrored by enhanced photic-induction of SCN c-Fos
(Smith et al., 2010; Benloucif et al., 2003; Kawaguchi et al.,
2003), findings that may be taken as consistent with the
current findings of atomoxetine enhancing the magnitude
of photically induced phase delays but attenuating light
induced c-Fos and ARC expression in the SCN. Of partic-
ular interest is the report by Smith et al. (2010) that NAN-
190, a 5-HT mixed agonist/antagonist that also has signif-
icant affinity for -1 adrenoreceptors, potentiates photically
nduced phase shifts while suppressing SCN c-Fos induc-
ion by light.
CONCLUSION
The findings that atomoxetine can alter circadian rhythmic-
ity is of possible clinical importance in considering the
mechanisms of its therapeutic effects in ADHD. Circadian
abnormalities, including phase-delays of the melatonin
rhythms and delayed sleep-onset insomnia have been
described in ADHD, as well as association with clock gene
polymorphisms (Van Veen et al., 2010; Van der Heijden et
al., 2005; Kissling et al., 2008). Given that atomoxetine
clearly has the potential to alter circadian phase, as well as
potential to alter entrainment to zeitgebers, it will be of
great interest for future studies to assess these issues in
patient populations. This may have far reaching implica-
tions for our understanding of the pathophysiology as well
as development of possible treatment strategies of neuro-
psychiatric disorders.
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